Know Cancer

or
forgot password

Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment


N/A
18 Years
N/A
Open (Enrolling)
Both
Cancer

Thank you

Trial Information

Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment


80 patients will be included in swiss-romande hospitals and private oncologists and followed
by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration
is 48 weeks, with a motivational interviewing at least every three months. Patient adherence
will be assessed electronically by MEMS (Medication Event Monitoring System).


Inclusion Criteria:



- 18 years and older

- Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib,
nilotinib, everolimus, deferasirox)

- French speaking

Exclusion Criteria:

- None

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Change in Medication adherence

Outcome Description:

MEMS data, completed by informations given in motivational interviewing

Outcome Time Frame:

3 months, 6 months, 9 months, 12 months

Safety Issue:

No

Principal Investigator

Bugnon Olivier, Professor

Investigator Role:

Study Chair

Investigator Affiliation:

Policlinique M├ędicale Universitaire

Authority:

Switzerland: Ethikkommission

Study ID:

139/10

NCT ID:

NCT01370980

Start Date:

July 2010

Completion Date:

September 2014

Related Keywords:

  • Cancer
  • Medication Adherence
  • Patient Compliance
  • Patient Acceptance of Health Care
  • Administration, Oral
  • Cancer
  • Letrozol
  • Exemestan
  • Imatinib
  • Sunitinib
  • Nilotinib
  • Everolimus
  • Deferasirox
  • Mouth Neoplasms

Name

Location